IAC Express 2008 |
Issue number 713: February 25, 2008 |
|
Contents
of this Issue
Select a title to jump to the article. |
- FDA
advisory panel selects influenza virus strains that will make up the U.S.
2008-09 vaccine; CDC press briefing reveals 12 additional pediatric
influenza deaths
- CDC
reports on measles outbreak in Pennsylvania, Michigan, and Texas during
August-September 2007
-
Important: Be sure to give influenza vaccine throughout the influenza
season--from now through spring
- CDC adds
to its Seasonal Influenza web section
- MMWR
publishes U.S. influenza update for September 30, 2007-February 9, 2008
- For
coalitions: March 11 is the date for IZTA's teleconference on building
media support for NIIW activities
-
Adolescent immunization symposium scheduled in Atlanta on March 18 to
coincide with NIC
- Adult
immunization conference scheduled for March 7 in Chaska, MN
|
|
Abbreviations |
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
|
Issue 713: February 25, 2008 |
|
|
1. |
FDA advisory panel selects
influenza virus strains that will make up the U.S. 2008-09 vaccine; CDC press
briefing reveals 12 additional pediatric influenza deaths
On February 25, the FDA website posted
information about the
vaccine strains that will compose the U.S. influenza vaccine for
the 2008-09 influenza season. The information is reprinted
below.
On February 22, CDC held a press briefing on the current
influenza situation in the U.S. Significant information included
the announcement that 22 laboratory-confirmed pediatric
influenza deaths have been reported to CDC for the current
influenza season. This is 12 more than CDC reported last week.
In addition, widespread influenza activity has been reported in
49 states. A link to a transcript of the February 22 press
briefing is given at the end of this IAC Express article.
FDA's Vaccines and Related Biological Products Advisory
Committee (VRBPAC) met in Gaithersburg, Maryland, on February
21, 2008, to select the influenza virus strains for the
composition of the influenza vaccine for use in the 2008-2009
U.S. influenza season. During this meeting, the advisory panel
reviewed and evaluated the surveillance data related to
epidemiology and antigenic characteristics, serological
responses to 2007/2008 vaccines, and the availability of
candidate strains and reagents.
The panel recommended that vaccines to be used in the 2008-2009
influenza season in the U.S. contain the following:
- An A/Brisbane/59/2007 (H1N1)-like virus
- An A/Brisbane/10/2007 (H3N2)-like virus
- A B/Florida/4/2006-like virus
A/Brisbane/10/2007 is a current southern hemisphere vaccine
virus. B/Florida/4/2006 and B/Brisbane/3/2007 (a
B/Florida/4/2006-like virus) are current southern hemisphere
vaccine viruses.
The influenza vaccine composition to be used in the 2008-2009
influenza season in the U.S. is identical to that recommended by
the World Health Organization on February 14, 2008, for the
Northern Hemisphere's 2008-2009 influenza season.
To access the information from the FDA website, go to:
http://www.fda.gov/cber/flu/flu2008.htm
To access the transcript of the February 22 CDC press briefing,
go to:
http://www.cdc.gov/od/oc/media/transcripts/2008/t080222.htm
Back to top |
|
|
2. |
CDC reports on measles outbreak in Pennsylvania, Michigan, and Texas during
August-September 2007
CDC published "Multistate Measles Outbreak
Associated with an
International Youth Sporting Event--Pennsylvania, Michigan, and
Texas, August-September 2007" in the February 22 issue of MMWR.
Portions of the article are reprinted below. The CDC website
offers healthcare professionals and the public a wealth of
information about measles disease and vaccine. A link to the
measles web section appears at the end of this IAC Express
article.
Measles, a highly infectious viral illness, is no longer endemic
in the United States because of high coverage rates with an
effective vaccine. However, imported cases continue to cause
illness and outbreaks among susceptible U.S. residents. In
August 2007, a participant in an international youth sporting
event who traveled from Japan to the United States became ill
with measles. Because he traveled while infectious to an event
with thousands of participants and spectators, an outbreak
investigation was conducted in multiple states by state and
local health departments in coordination with CDC, using
standard measles surveillance case definitions and
classifications. This report summarizes the results of that
investigation, which identified six additional measles cases
that were linked epidemiologically to the index case and two
generations of secondary transmission. Viral genotyping
supported a single chain of transmission; six of the seven cases
were linked by genetic sequencing. U.S. organizers of large-scale events attended by international travelers, especially
youths, should consider documentation of adequate participant
vaccination. This outbreak highlights the need to maintain the
highest possible vaccination coverage in the United States,
along with disease surveillance and outbreak-containment
capabilities.
A sporting event held in central Pennsylvania during August 17-26, 2007, included eight U.S. teams and eight international
teams representing Canada, Chinese Taipei, Curacao, Japan,
Netherlands, Mexico, Saudi Arabia, and Venezuela. Combined
participant and spectator attendance for the event was
approximately 265,000. Team members (boys aged 10-13 years) and
coaches resided in the same compound during the event, with a
common area shared by all teams. Access to the compound was
restricted to a small number of officials, corporate sponsors,
and event staff members.
Cases 1 and 2: Pennsylvania, Imported from Japan
A boy aged 12 years on the Japanese team (the index patient),
who had unknown vaccination status, had been exposed to a
sibling with measles-like illness in Japan in late July 2007.
The boy had a sore throat and malaise on August 11 and traveled
to the United States on August 13. The Japanese and Chinese
Taipei teams traveled together by aircraft from Tokyo, Japan, to
Detroit, Michigan, where they cleared immigration and customs,
and then traveled by aircraft to Baltimore, Maryland, where they
chartered a bus to Pennsylvania. On August 14, the patient
visited the event infirmary to be evaluated for his sore throat.
On August 16, he had a measles-compatible rash, cough, Koplik's
spots, fever (102.4 degrees F [39.1 degrees C]), and coryza. The
infectious period for measles extends from 5 days before to 4
days after rash onset. The Pennsylvania Department of Health
(PADOH) was notified, and the patient was isolated. Measles-specific immunoglobulin M (IgM) antibodies were detected in his
serum sample; urine culture yielded measles virus, genotype D5.
PADOH reviewed vaccination records for 481 players, coaches,
translators, and event staff members at the compound; 292 (61%)
either had documentation of 2 doses of measles-containing
vaccine or history of measles disease, or were born before 1957
and were, therefore, considered immune. The remaining 189 (39%)
were offered measles, mumps, and rubella (MMR) vaccine or
serologic testing; 104 chose to be vaccinated, and 85 chose
serologic testing. Sixteen (19%) of those tested lacked evidence
of immunity and subsequently were vaccinated. Public health
staff members and healthcare providers in Pennsylvania were
alerted through the state Health Alert Network, and public
announcements were issued. State health departments in
California, Georgia, and Texas were informed of potential
measles exposures among visiting corporate representatives who
had already attended the event and departed from Pennsylvania.
A second boy aged 12 years with unknown vaccination status who
had direct contact with the index patient only on August 12 in
Japan, arrived in the United States on August 15 to watch the
competition. On August 20, he had a sore throat and fever,
followed by cough and rash on August 23. On August 24,
nasopharyngeal, urine, and blood specimens were collected from
the boy at a local emergency department. He was placed in
isolation in his hotel room. His serum sample was positive for
measles-specific IgM antibodies. Nasopharyngeal culture yielded
measles virus genotype D5. The boy had minimal public
interaction during his infectious period and was deemed not
infectious during his airline travel.
The 29 members of his travel group and all 27 hotel staff
members were interviewed; 38 (68%) persons without adequate
evidence of immunity received MMR vaccine. Guests registered at
the hotel during the boy's infectious period were advised to
contact their physicians and local health departments in the
event of illness. No measles cases were identified among these
groups.
Cases 3 and 4: Michigan
In accordance with CDC protocol (CDC, unpublished document,
2008), passenger manifests for the August 13 Tokyo-Detroit and
Detroit-Baltimore flights were obtained to contact persons
seated within one row of the index patient. A woman aged 53
years seated one row in front of the index patient on the
Detroit-Baltimore flight acquired measles (case 3). Although
born in 1954, she recalled no history of measles or receiving
measles-containing vaccine and was administered immunoglobulin
prophylaxis after being identified as a contact. On August 25,
she had fever, cough, and coryza, followed by rash on August 28.
Serum initially was negative for measles IgM and immunoglobulin
G antibodies, but she subsequently seroconverted. Measles viral
RNA, detected in urine by reverse transcription-polymerase chain
reaction (RT-PCR), had an identical sequence to the genotype D5
sequences obtained from the two patients in Pennsylvania.
Case 4 was identified in a U.S.-born man aged 25 years who was
employed as a federal airport officer and had no documented
measles vaccination. The officer and the index patient had been
present in the same Detroit customs area on August 13. On August
23, the officer had wheezing, abdominal pain, and sweating,
followed by rash on August 27. A serum sample obtained August 30
was positive for measles IgM antibodies. Measles virus RNA was
detected by RT-PCR from a throat swab; however, attempts to
amplify the larger region of the N gene necessary for genotyping
were unsuccessful in this case.
A coworker of the officer at the same airport had measles 1
month later. The source of this infection could not be
determined; the coworker's measles might have been linked to
case 4 through an unrecognized chain of transmission (because
the incubation period for measles ranges from 7 to 18 days) or
might have resulted from a separate, unrelated exposure.
Cases 5, 6, and 7: Texas
Case 5 was identified in a U.S.-born man aged 40 years who was
employed as a corporate sales representative and had no
documented measles vaccination. The sales representative had met
the index patient on August 14 in Pennsylvania and had cough,
conjunctivitis, coryza, and fever on August 26. He had rash on
August 28 and was hospitalized the next day with a seizure,
fever of 105.7 degrees F (40.9 degrees C), and pneumonia.
Measles was confirmed by serum IgM antibodies and viral RNA
detected in urine by RT-PCR. He recovered and was discharged
from the hospital after 4 days.
Before his hospitalization, the man had made sales visits to
three Houston-area colleges. Cases 6 and 7 were identified among
male college roommates, aged 18 and 19 years, who had attended
one of the sales events on August 28. Both students were born in
the United States and had received 2 documented doses of MMR
vaccine. They had fever, chills, and myalgia on September 9 and
10, respectively; one had conjunctivitis. Both had rash on
September 11, detectable measles IgM antibodies in serum, and
measles virus RNA by RT-PCR in throat swab specimens. No
additional cases were identified. The genotype D5 sequences
obtained from the three Texas patients were identical to those
of the two patients from Pennsylvania and to one of the two
patients (case 3) from Michigan. On August 30, the outbreak was
reported to the World Health Organization under the revised
International Health Regulations as a public health emergency of
international concern. . . .
Because international events provide opportunities for measles
transmission, organizers of large gatherings attended by
international travelers, especially youths, should consider
documentation of adequate participant vaccination. To prevent
spread of measles, international travelers are encouraged to be
fully vaccinated. MMR vaccine, administered to susceptible
persons within 72 hours of measles exposure, is a recommended
intervention for measles outbreak containment. . . .
The attack rate of measles among susceptible persons has been
documented as >90%. Previous imported measles cases have
demonstrated the potential for larger outbreaks in U.S.
communities with poor vaccination coverage. The small number of
identified cases in this outbreak, despite the large number of
exposed persons, demonstrates the value of maintaining high
measles vaccination coverage in the U.S. population through
adherence to routine vaccination recommendations. This outbreak
also highlights the continuing importance of promoting measles
control and elimination in other countries and sustaining strong
surveillance and response measures in the United States. . . .
To access a web-text (HTML) version of the complete article, go
to: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5707a1.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to: http://www.cdc.gov/mmwr/PDF/wk/mm5707.pdf
To receive a FREE electronic subscription to MMWR (which
includes new ACIP statements), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
A CDC web section provides the public with information about
measles disease and vaccine, beliefs and concerns, vaccine
safety, and persons who should not be vaccinated. It provides
healthcare professionals with clinical information,
recommendations, references and resources, provider information
and materials for patients. To access the CDC measles web
section, go to: http://www.cdc.gov/vaccines/vpd-vac/measles
Back to top |
|
|
3. |
Important: Be sure to give influenza vaccine throughout the influenza
season--from now through spring
Influenza is currently circulating and
vaccination should
continue from now until April and May. Visit the following
websites often to find the information you need to keep
vaccinating. Both are continually updated with the latest
resources.
The National Influenza Vaccine Summit website at
http://www.preventinfluenza.org
CDC's Seasonal Flu web section at http://www.cdc.gov/flu
Back to top |
|
|
4. |
CDC adds to its Seasonal Influenza web section
CDC recently added five resources to its Seasonal
Flu web
section:
-
"Updated: CDC influenza pandemic operation plan (OPLAN) from
January 11, 2008"
-
"The 2007-2008 flu season"
-
"Seasonal flu vaccine"
-
"Influenza antiviral drug resistance"
-
"Misconceptions about influenza and influenza
vaccine"
To access these resources, go to:
http://www.cdc.gov/flu/whatsnew.htm and click on the pertinent
link.
To access a broad range of continually updated information on
seasonal influenza, avian influenza, pandemic influenza, and
swine influenza, go to: http://www.cdc.gov/flu
Back to top |
|
|
5. |
MMWR publishes U.S. influenza update for September 30, 2007-February 9, 2008
On February 15, CDC published "Update: Influenza
Activity--United States, September 30, 2007-February 9, 2008" as an MMWR
Early Release. On February 22, CDC published the update in the
MMWR.
To access the update in the February 22 MMWR, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5707a4.htm
To access the February 22 MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5707.pdf
Back to top |
|
|
6. |
For coalitions: March 11 is the date for IZTA's teleconference on building
media support for NIIW activities
The Immunization Coalitions Technical Assistance
Network (IZTA)
March 11 conference call will provide tips and ideas on how
coalitions can build media support for National Infant
Immunization Week (NIIW) activities. Coalitions will also learn
about CDC's NIIW media materials and tools. IZTA is a program of
the Center for Health Communication, Academy for Educational
Development.
The March 11 call will be held at 1PM, ET. To register, send an
email to izta@aed.org Include this message: "Sign me up for the
building media support call."
For additional information, or to access earlier programs, go
to: http://www.izta.org/confcall.cfm
Back to top |
|
|
7. |
Adolescent immunization symposium scheduled in Atlanta on March 18 to
coincide with NIC
Adolescent Immunization: A New Focus on the Next
Generation is scheduled for the Georgia Aquarium in Atlanta the evening of
March 18, which coincides with the National Immunization Conference,
scheduled in Atlanta March 17-20. Sponsored by Albert Einstein College of
Medicine and Montefiore Medical Center, the adolescent symposium offers
attendees Continuing Medical Education and Continuing Education credits.
Pre-registration is advised by 4PM, ET, March 17.
To access the symposium brochure and online registration information, go to:
http://w4.isisgold.com/adolimmunatlmar08
To reach the registration hotline, call (800) 636-1668.
Back to top |
|
|
8. |
Adult immunization conference scheduled for March 7 in Chaska, MN.
Presented by the Minnesota Coalition for Adult
Immunization, "Issues and Strategies in Adult Vaccine-Preventable Diseases"
is scheduled for March 7 at the Minnesota Landscape Arboretum, Chaska, MN.
The registration deadline is February 29.
To access the conference brochure and register online, click
here.
For additional information, contact Mari Drake at
maridrake@comcast.net or (651)
428-6591.
Back to top |
|
|
|